epirubicin has been researched along with Carcinoma, Basal Cell, Pigmented in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balatoni, T; Biró, K; Danyi, T; Géczi, L; Küronya, Z; Liszkay, G; Tóth, E | 1 |
| Cornelissen, S; de Bruin, M; de Vries, EGE; Froklage, FE; Hauptmann, M; Holtkamp, M; Linn, SC; Lips, EH; Nederlof, PM; Rodenhuis, S; Schmidt, MK; Schrama, JG; van Beers, EH; van de Vijver, MJ; van Tinteren, H; Vollebergh, MA; Wesseling, J; Wessels, LFA | 1 |
1 trial(s) available for epirubicin and Carcinoma, Basal Cell, Pigmented
| Article | Year |
|---|---|
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Breast Neoplasms; Carboplatin; Carcinoma, Basal Cell; Comparative Genomic Hybridization; Cyclophosphamide; DNA Methylation; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Mutation; Promoter Regions, Genetic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Thiotepa; Treatment Outcome | 2011 |
1 other study(ies) available for epirubicin and Carcinoma, Basal Cell, Pigmented
| Article | Year |
|---|---|
Atezolizumab for the treatment of advanced recurrent basal cell carcinoma and urothelial carcinoma of bladder: a case report.
Topics: Aged; Antibodies, Monoclonal; Carcinoma, Basal Cell; Carcinoma, Transitional Cell; COVID-19; Epirubicin; Female; Humans; Immune Checkpoint Inhibitors; Skin Neoplasms; Urinary Bladder; Urinary Bladder Neoplasms | 2022 |